Semaglutide liver fat quantification — MRI-PDFF data from multiple trials

I'm a bit confused. I thought GLP-1 drugs were for weight loss and diabetes. How does something that reduces appetite protect the kidneys? What's the actual mechanism?

Excellent question. The renal benefit likely involves multiple mechanisms beyond weight loss and glucose control:

1. Reduced intraglomerular pressure: GLP-1 promotes natriuresis (sodium excretion) at the proximal tubule, which reduces glomerular hyperfiltration — a major driver of CKD progression
2. Anti-inflammatory effects: CKD is characterized by chronic kidney inflammation. GLP-1 RAs reduce renal expression of inflammatory mediators (NF-κB, MCP-1)
3. Anti-fibrotic effects: Preclinical data shows GLP-1 RAs reduce TGF-β signaling and renal fibrosis
4. Improved endothelial function: Better renal blood flow autoregulation
5. Metabolic improvements: Better glycemic control, reduced hyperinsulinemia, lower blood pressure, and improved lipids all independently benefit kidney health

GLP-1 receptors are expressed throughout the kidney, including in the proximal tubule, glomerular endothelium, and juxtaglomerular apparatus. So this is not just a systemic metabolic effect — there's direct renal pharmacology at work.

I'll add one more critical point: FLOW also showed a 20% reduction in all-cause mortality (HR 0.80; 95% CI, 0.67-0.95). This is arguably the most important finding because mortality is the hardest endpoint to move.

For a population with T2DM and CKD — which carries a 5-year mortality rate of 20-30% — a 20% relative mortality reduction translates to a meaningful number of lives saved. Combined with the evidence from SELECT (where semaglutide trended toward mortality reduction in the CV population), we're seeing a consistent signal that semaglutide extends life.

The early trial termination for efficacy should underscore the robustness of these findings. Data monitoring committees don't make that decision lightly — it means the evidence was so strong that it would have been unethical to continue withholding the drug from the placebo group.

Thank you all for this discussion. Very helpful for someone like me who is living with CKD and T2DM. I feel much more informed about why my nephrologist is adding semaglutide and what I should expect. The eGFR slope data is particularly encouraging — slowing the decline by 47% could mean years more before I'd need dialysis, if ever.

I'll share my labs after 6 months on the combination regimen.